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Purpose: The tyrosine kinase inhibitor (TKI) imatinib has improved outcomes for patients with 
unresectable or metastatic gastrointestinal stromal tumors (GIST), and for patients receiving 
adjuvant therapy following GIST resection. This qualitative study explored the experiences and 
emotions of patients through GIST diagnosis, treatment initiation, disease control, and in some 
patients, loss of response and therapy switch.
Patients and methods: Ethnographic investigations were conducted, including semi-
  structured qualitative interviews of patients with resected or metastatic/unresectable GIST and 
their caregivers, from Canada (n = 15); the United States (n = 10); and Brazil, France, Germany, 
Russia, and Spain (n = 5 each). Some interviewees also kept 7-day photo journals. Responses 
were qualitatively analyzed to identify gaps and unmet needs where communication about 
disease, treatments, and adherence could be effective.
Results: Patients shared common experiences during each stage of disease management (crisis, 
hope, adaptation, new normal, and uncertainty). Patients felt a sense of crisis during diagnosis, 
followed by hope upon TKI therapy initiation. Over time, they came to adapt to their new lives 
(new normal) with cancer. With each follow-up, patients confronted the uncertainty of becom-
ing TKI resistant and the possible need to switch therapy. During uncertainty many patients 
sought new information regarding GIST. Cases of disease progression and drug switching 
caused patients to revert to crisis and restart their emotional journey. Patients with primary or 
unresectable/metastatic GIST shared similar journeys, especially regarding uncertainty, although 
differences in the scope and timing of phases were observed. Strategies patients used to remain 
adherent included obtaining family support, setting reminder mechanisms, taking medicine at 
routine times, and storing medicine in prominent places.
Conclusions: Physicians and support staff can manage patient expectations and encourage 
adherence to therapy, which may facilitate optimal patient outcomes. Patient education about cur-
rent GIST developments and adherence across all phases of the patient journey are of benefit.
Keywords: Gastrointestinal stromal tumors, medication adherence, compliance, imatinib, 
qualitative study, ethnographic investigation
Introduction
Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors 
of the gastrointestinal tract.1 GIST most commonly occur in the stomach (60%–70%) 
or small intestine (20%–25%) at a rate of 20 cases per million persons per year.2,3 The 
introduction of the tyrosine kinase inhibitor (TKI) imatinib (Glivec®/Gleevec®, Novartis 
AG, Basel, Switzerland) has improved the treatment of KIT+ GIST.   Clinical results 
have shown improvements in response rates and progression-free survival for patients 
with unresectable and/or metastatic KIT+ GIST treated with imatinib at doses between 
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400 mg/day and 800 mg/day.4,5 Interruption of imatinib after 
1, 3, or 5 years has been associated with increased risk of 
relapse, even in patients who achieve complete response, 
suggesting that continuous therapy may be necessary until 
disease progression or intolerance occurs.6,7 As such, adher-
ence to self-administered imatinib therapy is an essential 
component of the daily routine of these patients, and adher-
ence evaluation is a key component of disease management 
for health care providers (HCPs).
The clinical benefit of imatinib as adjuvant therapy, given 
for 3 years after resection in patients with KIT+ GIST, has been 
validated in the randomized Phase III Scandinavian Sarcoma 
Group (SSG)/Sarcoma Group of the Arbeitsgemeinschaft 
Internistische Onkologie (AIO; SSGXVIII/AIO) trial.8 
Although surgery is considered the only curative treatment for 
primary resectable GIST, even after complete resection, almost 
50% of patients experience disease recurrence within 5 years.9 
As a result, imatinib is indicated for adjuvant treatment of 
adult patients following resection of GIST expressing KIT 
(CD117),10–12 and the National Comprehensive Cancer Network 
(NCCN) guidelines suggest a duration of at least 36 months of 
imatinib in patients at high risk of recurrence.11
Targeted, oral medications are being developed increasingly 
for cancer treatment. In spite of the severity of many cancers, 
adherence to these self-administered medications can be a 
challenge. One study showed that patients taking oral cancer 
medications may overestimate their adherence to therapy by 
a factor of 2.13 Results from another study of patients with 
KIT+ GIST or Philadelphia chromosome-positive chronic 
myeloid leukemia on imatinib therapy showed that only half 
of the patients achieved 100% compliance over a 24-month 
period.14 Moreover, a comprehensive patient record review of 
patients with GIST (adjuvant: 147 records; metastatic: 225 
records) who were treated with imatinib showed that less than 
half of the patients were perfectly compliant over their last 
four prescription refills (all refills exactly on time; data not 
published). In addition, approximately 10%–14% of GIST 
patients missed 10% or more of their prescribed daily dose 
during the last four refills in the study.
Effective management of adverse events (AEs) in patients 
with GIST can facilitate continued treatment and adherence to 
TKI treatment. Although imatinib is generally well tolerated, 
virtually all patients with metastatic GIST (.95%) who have 
been treated with imatinib experienced at least one AE of any 
grade.4,15–18 However, many of the AEs occurring in imatinib-
treated patients with metastatic GIST may be related to 
surgical procedure, underlying malignancy, or other illnesses 
that may occur during prolonged imatinib administration.
Significantly longer progression-free survival has been 
observed in patients with metastatic disease on continuous 
imatinib therapy compared with patients whose therapy 
was stopped after 1, 3, or 5 years.6,7,18 Even for patients 
who have achieved complete response, discontinuation can 
result in loss of remission and rapid tumor progression.6 
Moreover, interruption of continuously scheduled treat-
ment due to nonadherence or other reasons can lead to low 
imatinib plasma concentrations, which have been reported 
to be associated with a short median time to progression for 
patients with advanced GIST, confirming the importance of 
maintaining optimal drug levels through adherence.19 Dose 
escalation of imatinib may be considered in patients showing 
objective signs of disease progression at a lower dose and in 
the absence of severe adverse drug reactions.11 In cases where 
maximum supportive care with imatinib is not effective, 
or where imatinib results in life-threatening side-effects, 
sunitinib is recommended as second-line therapy.11
The treatment of GIST involves not only an understanding 
of medical therapy regimens and their associated AEs, but also 
an understanding of the patient emotional journey through 
diagnosis and treatment. The current study explored the GIST 
patient journey from diagnosis through the start of TKI treat-
ment, initial response, if any, to treatment, loss of response in 
a subset of patients deriving clinical benefit from TKI therapy, 
and subsequent switching to second-line or investigational 
therapies. Ethnographic tools to examine patients’ experience 
with issues such as adherence, disease knowledge, disease 
management, and relationship with HCPs were used.
Methods
Study design
Patients were recruited from individual clinical practice 
centers. Exclusion criteria included: patients working in 
advertising; marketing/market research; public relations; 
any media (eg, TV , radio); the pharmaceutical industry; the 
health care industry as physicians, pharmacists, mental health 
professionals, or registered/licensed nurses; and patients aged 
younger than 21 years or older than 80 years.
The ethnographic approach sought to engage patients with 
GIST in their own environments to obtain open feedback on 
their everyday experiences. Multiple, in-context techniques, 
including individual and group interviews, life histories, and 
participant observation, were used. Together, these methods 
served to elicit patients’ perspectives on their disease and 
  treatment. Researchers documented all interactions and 
observations with participants by taking field notes; these notes 
were then examined to address key topic areas (see ‘Content and 
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questions’ section). Patient perspectives were then compared, 
and any emerging concepts or themes were assembled.
The main approach included a 2.5-hour, in-home inter-
view with patients who either had resected or metastatic 
GIST, and their immediate family members. The patient sam-
ple comprised North American (United States and   Canada) 
and global patients (Brazil, France, Germany, Russia, and 
Spain). After the interview, patients from North America, 
Brazil, and France completed a 7-day photo journal followed 
by a 45-minute telephone interview. All patients provided 
written consent to participate in the investigation. Patient 
privacy is maintained based on a signed consent agreement 
between the researchers and the patient participants and their 
families. Per the consent document, we maintain GIST patient 
anonymity but have permission to use patient quotes.
Content and questions
The ethnographic interview protocol included seven   sections 
with suggested discussion time limits to provide a general 
structure to the interview (Table 1). These seven sections 
addressed issues relating to daily life, management techniques 
for adherence and TKI-related side-effects, their relation-
ship with their HCP, and how these patients perceived their 
disease and associated treatment options. Questions were 
developed by the investigators with input from specialists as 
well as psychosocial scientists trained in evaluating patient 
experiences. The interviews were audiotaped. National data 
were analyzed by researchers at each site, and the composite 
national results for the global dataset were then analyzed by 
two independent researchers.
Results
Participants and settings
Fifty patients with GIST were interviewed and included in 
the study (Table 2). A total of five patients from each country 
outside North America with either (a) resected primary 
GIST who received adjuvant imatinb therapy (n = 2), or 
(b) metastatic GIST who received TKI treatment (n = 3), 
were interviewed between February 15, 2010, and May 31, 
2010. The North American country samples consisted of 
ten patients from the United States (adjuvant) and 15 from 
Canada (n = 5, adjuvant; n = 10, metastatic) who were inter-
viewed between January 19, 2010, and April 19, 2010.
Overview of the stages of the GIST 
patient journey
The GIST patient journey included stages of: crisis, hope, 
adaptation, new normal, and uncertainty (Figure 1). Patients 
experienced crisis when they were given the diagnosis of GIST 
and were faced with the ensuing treatment decisions that spark 
worry about the road ahead and mortality. The crisis dissipated 
as patients saw a therapeutic path forward, and hope emerged 
with drug treatment, and in those patients who had an early 
response, followed by disease regression or stability. Patients 
then entered a period of adaptation, where a prolonged period of 
adjustment required changes in behavior, outlook, and lifestyle. 
This period culminated in altered expectations and acceptance 
of a new outlook on life. Most patients eventually “moved 
on with life” in the stage of new normalcy. The new normal 
Table 1 Interview protocol
Section Main topic Subtopics
1 (10 minutes) Personal/family  
context
• Background 
• Family 
• Employment
2 (45 minutes) Illness and  
treatment history
• Medical history (timeline) 
• Diagnosis 
• Treatment history 
• Experience with imatinib 
• Role imatinib plays in your life 
•   Diagnostics and switching 
medications
3 (20 minutes) Relationship with  
medical team
• Physicians and facilities 
• Provider selection process 
• Frequency of visits 
• Quality of relationship 
•   Source of education about 
disease and treatments
4 (20 minutes) Current  
management  
of illness
• Logistical and financial concerns 
•   Educational resources for 
disease treatments
• Routines to help manage disease 
• Lifestyle modifications
5 (15 minutes) Support • Family support 
• Provider support 
• Other resources
6 (20 minutes) Impact of cancer 
on life
• Emotional impact
7 (20 minutes) Medicine cabinet  
tour
• Locations of medications 
• Medication adherence routines
Table 2 GIST treatment setting and patient nationality
Country Adjuvant patients Metastatic patients
Brazil 2 3
Canada 5 10
France 2 3
Germany 2 3
Russia 2 3
Spain 2 3
United States 10 0
Abbreviation: GIST, gastrointestinal stromal tumors.
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for these patients was markedly different, both mentally and 
physically, from their life before receiving a GIST diagnosis. 
The stage of uncertainty included fear of and/or experience of 
treatment failure that precipitated anxiety about the disease. 
  Progression triggered crisis, and during this stage patients com-
monly searched for information on GIST and new treatment 
options that would bring the disease back under control. Patients 
progressed through these stages over time, and the stages 
were abbreviated or prolonged depending on the degree of 
each individual’s disease (eg, primary resected or metastatic, 
comorbidities), therapy response, and circumstances.
The patient journey has changed with the availability of 
new clinical treatment options, information resources, and 
disease awareness among patients and physicians. The suc-
cess of imatinib has altered how patients think about GIST; 
patients noted that they considered TKI treatment to be “easy” 
compared with how they perceived other cancer treatments 
are (ie, chemotherapy), and the proven outcomes of imatinib 
gave physicians confidence and gave patients optimism. The 
evolution of cancer treatment paradigms with new therapies 
provides imatinib-resistant or imatinib-intolerant patients with 
additional treatment options. These additional options along 
with improved outcomes meant that the uncertainty was not 
always a result of drug resistance or disease progression, but 
could also result from anxiety surrounding disease monitor-
ing, treatment side-effects, or dose changes.
The GIST patient journey has been extended with the advent 
of second-line treatment with the multitargeted TKI sunitinib 
(Sutent®; Pfizer, New York, NY) and other investigational 
therapies currently in development. The NCCN guidelines 
recommend sunitinib 37.5 mg once daily without interruption 
or sunitinib 50 mg once daily on a schedule of 4 weeks on 
followed by 2 weeks off.11 When a patient can no longer 
tolerate, or becomes resistant to, imatinib, second-line and 
investigational therapies can offer hope, but these therapies 
can also cause patients to revisit earlier journey stages. Patients 
reported returning to a period of crisis with disease recurrence 
(adjuvant patients) or progression (metastatic patients). With 
the assistance of their HCPs and support network, patients may 
then readapt to the new stage of their journey followed by a 
different new normal period.
Crisis
For patients with GIST, diagnosis of the disease began the 
tumultuous journey of discovery about GIST and its associ-
ated prognoses, treatment options, and paradigms. Regard-
less of the time to the diagnosis of GIST, the stage of crisis 
inevitably ensued. In the case of protracted diagnoses, many 
patients had longstanding indeterminate symptoms, or the 
sense of knowing that something was “not right.” Some 
patients went through months, even years, of anxiety, gener-
alized symptoms, and declining health before receiving the 
diagnosis of GIST. One patient said, for example:
“It took months. I went to a doctor, and he didn’t know what 
was wrong. They did one gastroscopy and colonoscopy 
after another until they finally did a [computed tomography 
scan] – then they knew it.”
Some patients received the diagnosis quickly and inci-
dentally, or after an acute event. One patient explained, for 
example:
“[In a routine procedure] they found a bump on my rectum, 
but I thought it was no big deal. The shock was a week later 
when the doctor called and said it was a very rare disease 
called GIST.”
Diagnosis
Crisis Hope Adaptation New normal Uncertainty
Treatment
initiation
Response and
monitoring Chronic management
Resistance/
progression/
change
Figure 1 The GIST patient journey diagram. The various stages are not drawn to any scale in regard to duration, and time spent in each stage may vary between 
individual patients.
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Patients reported that shock is a central part of crisis, 
which results from diagnosis, because GIST is relatively 
unknown to most patients, who have never heard of this 
disease. The feeling of fear was heightened in patients who 
were told by their HCPs that they had a “rare” disease.
At diagnosis, patients learned that they had a tumor, but 
most patients reported that the word “cancer” was not part 
of the conversation. Few patients reported hearing this word 
at diagnosis. For example:
“The diagnosis was evasive. The radiologist said ‘GIST’, 
but at the time GIST didn’t mean cancer. But [my wife] 
checked out the Internet and saw it was cancer.”
Hope
For patients, hope came from the knowledge that there is an 
existing treatment with proven efficacy in GIST, so that they 
could see a path forward. Some patients felt psychologically 
reassured and physically improved when they began treat-
ment. As one patient explained:
“They said [the therapy] might shrink the tumor. I felt 
better quickly, fantastic, in 2 weeks. It was an amazing 
  difference. I learned later that shrinkage meant it would 
liquefy [ie, cystification] inside.”
Hope also fueled patients’ search for current information 
about their disease and its associated treatment options. Many 
patients reported encountering out-of-date, contradictory, or 
incorrect information, which was confusing at times, as well 
as anxiety provoking. For example:
“I checked Google with “stromal tumors” or “GIST.” Google 
seemed to show older results, dating back to 2002 or 2003, 
and that was worrisome.”
Although patients uniformly grasped the idea that ima-
tinib is a treatment and not a cure for metastatic GIST, dif-
ferences in the levels of confusion arising from undefined 
treatment durations were observed for patients with different 
treatment modalities (ie, therapy in the adjuvant or metastatic 
and/or unresectable disease settings). Patients with metastatic 
GIST understood that they would most likely be on therapy 
for life. However, many patients who underwent surgery 
for primary GIST were unsure how long they would receive 
adjuvant treatment, because their HCPs were themselves 
unsure. The optimal duration of adjuvant imatinib treat-
ment is currently unknown. As a result, treatment duration 
for these patients is commonly not specified by physicians 
upfront, and patients reported that imatinib therapy came 
with an indeterminate timeline they found to be unsettling. 
As one patient explained:
“With metastases, you will be treated with [imatinib] 
automatically, but clinical data is not clear for adjuvant. 
Everybody has his own opinion here.”
Patients also expressed frustration at the lack of commu-
nication and coordination among the physicians responsible 
for their treatment. Patients reported that surgeons failed to 
set postsurgical expectations, while oncologists were focused 
on treating the cancer but provided little guidance on post-
surgical lifestyle management.
Adaptation
As patients with GIST settled into medical therapy, they 
struggled with profound changes. Patients progressed through 
a period of adaptation, whereby they came to terms with 
the course of events: a cancer and/or rare-disease diagnosis, 
surgery, medications, and a harsh confrontation with their 
own mortality. During this transitory period, many patients 
reported suffering from symptoms of depression, anxiety, and 
insomnia. Adaptation also brought the physical challenges of 
postsurgery functionality, including changes in diet brought 
about by altered digestion, and more broad-spectrum lifestyle 
changes arising from increased fatigue. For example:
“Anyone who goes through a gastrectomy knows that things 
don’t work the same anymore. I used to wonder if my symp-
toms were from the drug, but now I know that these things 
are due to my surgery. They took out a lot of parts!”
Adaptation meant an altered sense of the patient’s own 
body. Patients expressed a myriad of feelings about hav-
ing cancer in their bodies, referring to it as an “invader” or 
“alien.” During this stage, patients with metastatic GIST 
adjusted to the continuous presence of cancer, while patients 
in the adjuvant setting adjusted to the potential risk for recur-
rence. Although few understood the cause of the cancer, 
many reported that GIST was a “wake-up call.” Many became 
focused on the “important” things in life, such as families, 
relationships with others, and spirituality during this stage.
Over time, patients with GIST developed methods for 
managing their disease and treatment (ie, self-care). A key 
element of developing self-care involved coming to terms 
with the necessity of drug adherence, either in the adjuvant 
or metastatic disease setting. Most patients were motivated 
to take their medication, as it gave them an active role in 
their long-term health. Many patients acknowledged that it 
took time to develop steady, consistent, drug-taking routines, 
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and that they needed to adapt and learn to manage treatment 
side-effects.
During adaptation, patients also developed a sense of 
personal advocacy, whereby they fostered and strengthened 
new relationships with their HCPs and other members of the 
GIST community. Having recognized that GIST is a disease 
that few people know about or understand, many patients felt 
“singled out” and were obliged to become their own best 
advocates. As a means of personal advocacy, patients sought 
out GIST specialists and often sought guidance from other 
patients dealing with similar experiences by participating in 
online communities. This personal momentum may help con-
tribute to patients returning to a new sense of normalcy.
New normal
For patients with GIST, the new normal stage meant achiev-
ing a semblance of life pre-GIST diagnosis. New normal 
came as patients moved beyond merely adapting to their new 
circumstances, but started participating in activities within 
their new circumstances; for many, it was a time of returning 
to activities they used to do.
Of special note, all participating patients claimed that the 
need to adhere to TKI therapy was a prevailing thought during 
this stage, and most claimed that they had established routines 
to try to remember to take their medications. For example, 
many patients stored their drugs in the kitchen; some also 
reported filling pill boxes at a given time each week. Other 
strategies patients used to remain adherent included: hav-
ing a family member remind them to take their medication, 
setting reminder mechanisms, and keeping a calendar. In 
addition, some patients took their medication at regularly 
spaced periods during the day, while others took it all at once 
at a specific time. Patients also viewed TKI therapy as an 
“insurance policy” against progression (those with metastatic 
and/or unresectable disease) and recurrence (those receiving 
adjuvant therapy). For example:
“When I walk my dog, I take a golf club, just in case the 
coyotes return. I consider my [imatinib] to be like a golf 
club, something there to protect me just in case the cancer 
returns.”
For patients with GIST, normal life was punctuated by 
moments of fragility. All patients experienced increased 
anxiety leading up to their quarterly or biannual checkups, 
which included surveillance imaging scans; this increased 
stress is referred to, in the GIST community, as “scanxiety.” 
In response to being informed of an “all-clear” scan (ie, no 
detected progression or recurrence), patients felt a palpable 
sense of relief, and some reported feeling they now had 
“time to breathe.”
“When my doctor tells me that I am still cancer free, I feel so 
many emotions. … I pretty much live from scan to scan.”
Most patients with GIST in this study became “hyper-
surveillant” with their health. This attitude was evident 
regardless of treatment setting (metastatic or adjuvant), or 
time since diagnosis. Patients were sensitive to any physical 
changes that could signal progression (for metastatic disease) 
or recurrence (for resected GIST). Although patients in this 
study began to wonder what long-term TKI therapy may be 
doing to their bodies, few expressed strong concerns about 
potential side-effects arising from the long-term therapy. For 
most patients, their desire to continue treatment outweighs 
the potential risks.
The new normal did not mean complete resolution of all 
patients’ emotional issues and concerns. Patients had trouble 
conceptualizing the details of their cancer, and perceived 
their disease in absolute dichotomous terms (ie, they either 
had GIST or were disease-free). The degree of tumor burden 
was irrelevant to patients, and all wanted their tumor “gone.” 
Patients with metastatic GIST were clearly aware that their 
cancer was ever-present. Patients treated in the adjuvant 
setting worried that their current state – “no evidence of 
disease” – was tenuous or temporary. Many patients believed 
that tumor biopsies at diagnosis may have seeded cancer in 
their bodies, or that surgeons may not have achieved clear 
margins during resection. These preconceptions lead to a 
relative degree of uncertainty about the nature of their illness 
and its associated treatments.
Uncertainty
Patients experienced periodic episodes of uncertainty for var-
ious reasons along their disease journey and at various times. 
Clinical changes, uncertain test results, and new disease 
symptoms or treatment side-effects triggered uncertainty, 
whereby patients regressed to previous emotional patterns. 
Patients in both the adjuvant and metastatic settings in this 
study tended to cycle back through all the stages (crisis, hope, 
adaptation, new normal) during episodes of uncertainty; 
adjuvant patients responded to potential events or symptoms 
with emotions similar to metastatic patients, despite their lack 
of evidence of disease.
Many patients with GIST felt the need to stay abreast of 
new information. However, new scientific data, especially 
for adjuvant therapy, could trigger uncertainty. For example, 
reading new GIST studies or new clinical trial data led to 
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anxiety as patients interpreted or misinterpreted results. 
Patients on adjuvant therapy carefully followed changing 
information about duration of treatment and were continu-
ously concerned with whether stopping adjuvant therapy 
would allow for disease recurrence.
Switching therapy due to TKI resistance, disease recur-
rence, or progression was a key trigger for uncertainty and 
often precipitated a step back in the emotional journey 
 ( Figure 2). Patients believed that this meant that the worst 
outcome had occurred, and many patients reverted to crisis. 
Most patients were devastated by TKI failure and their 
unknown future path. Switching therapies also revived 
information-seeking behavior as patients re-energized around 
the need for personal advocacy. For example, one patient 
questioned:
“What will happen now? Will this new drug work as well 
as [the last drug]?”
Switching drugs due to intolerance often brought relief 
instead of crisis. Metastatic or adjuvant patients who suf-
fered intolerance to a TKI often readapted to the new therapy 
with relative ease, and their physical and emotional outlooks 
improved considerably after switching. Eventually these 
patients settled back to the normalcy of tolerable side-effects 
and good response. Conversely, emergence of new side-
effects after switching therapy could lead affected patients 
to experience crisis, as one patient explained:
“When I went on the [new] med, it was really tough. I had 
a hard time on it, because of the side-effects. Compared 
to what I am enduring now, [the prior therapy] was a 
cakewalk.”
Discussion
This global ethnographic study explored the GIST patient 
journey from diagnosis, through initiation of treatment, 
response to treatment in most patients, loss of response, 
and switching to second-line or investigational therapies. 
The study revealed that patients with GIST progressed 
through periods of crisis, hope, adaptation, new normal, 
and uncertainty.
For patients with metastatic GIST, persistent uncertainty 
represented the overriding reality (Figure 3). The impact 
of the disease was very high, and each stage of the journey 
was difficult. Crisis involved making high-stakes decisions 
within a vacuum of knowledge and misunderstanding. Hope 
for treatment success was tempered by the reality of a lim-
ited prognosis. Adaptation was prolonged and painful, and 
coming to terms with the presence of cancer was daunting. 
The new normal was a fragile time – physically sustainable 
but emotionally tumultuous. Uncertainty was a frequent 
occurrence even with stable disease, coinciding with anxiety 
experienced in anticipation of HCP visits and scans.
The adjuvant GIST patient journey displayed many 
similarities to the journey of the metastatic patient   (Figure 4). 
However, the adjuvant patient experienced hope in treatment 
success tempered by ongoing or recent medical intervention 
(eg, surgery). The adaptation stage for these patients was also 
difficult. Shortly after resections and despite no evidence of 
disease, physical changes arising from surgery were profound, 
and emotions were raw. Patients’ new normal was also imper-
fect, as they were hypervigilant about physical changes asso-
ciated with surgery and treatment. In addition, patients with 
GIST in both the adjuvant and   metastatic   settings experienced 
Crisis Hope Adaptation New normal Uncertainty
“New crisis” “Readaptation” “Back to (new) normal”
Switching
Figure 2 Switching therapy can lead to uncertainty and often precipitates a step back in the emotional journey. The various stages are not drawn to any scale in regard to 
duration, and time spent in each stage may vary between individual patients.
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GIST
patients
arrive at
diagnosis
after a long
history of
crisis
Negative
Positive
Emotional
impact on
patient
Crisis Hope Adaptation New normal Uncertainty
Impact on life
decreases
during initial
treatment
Practical impact of physical
changes and treatment SEs
create emotional turmoil
and practical difficulties
Most GIST patients reside
in a very altered sense of
normalcy, but are grateful
for the reprieve
New tumors,
resistance, and
progression are
constant threats
Metastatic GIST
Figure 3 The metastatic GIST patient journey. The various stages are not drawn to any scale in regard to duration, and time spent in each stage may vary between individual 
patients.
Abbreviations: GIST, gastrointestinal stromal tumors; SEs, side-effects.
GIST patients
arrive at
diagnosis
after a long
history of
crisis or a
sudden
intense
event
Negative
Positive
Emotional
impact on
patient
CrisisH ope Adaptation New normal Uncertainty
The impact
of medical
intervention
continues
indefinitely in
neoadjuvant
therapy, and
surgeries
prolong
anxiety
Despite ‘no evidence of
disease’, the practical impact
of physical changes and
treatment SEs create
emotional turmoil and
practical difficulties
Despite ‘no evidence of
disease’, hypervigilance
mars the return to a strong
sense of normalcy’
Disease
recurrence
remains a
profound threat
Adjuvant GIST
Figure 4 The adjuvant GIST patient journey. The various stages are not drawn to any scale in regard to duration, and time spent in each stage may vary between individual 
patients.
Abbreviation: GIST, gastrointestinal stromal tumors.
“scanxiety” prior to follow-up examinations (ie, uncertainty 
about the constant threat of disease recurrence/progression 
that heightened during their follow-up periods).
The patients with GIST in this study were highly self-
directed, but they encountered challenges finding accurate, 
relevant, and available information about GIST. Although 
a strong sense of personal advocacy drove the search for 
information, what patients learned was not always accurate, 
or they misinterpreted results from clinical trials. Thus, each 
interaction between a patient and an HCP offers a critical 
opportunity to clarify and reinforce accurate and relevant 
information. Physicians also could reinforce and support 
their search and ensure that the information patients receive 
is appropriate by directing them to medically accurate GIST 
support materials and communities. The provision of accurate 
information may lead to a greater sense of independence and 
fewer touch points with HCPs. For patients transitioning from 
crisis to hope, HCPs can help set expectations around drug 
efficacy and differentiate among treatments. HCPs can also 
help patients understand the real risk of disease progression 
and recurrence by educating them about the effectiveness of 
TKI therapy and providing a roadmap to those with GIST 
in the adjuvant setting to help them understand issues sur-
rounding duration of treatment. Additionally, to reduce the 
risk of relapse or recurrence, the importance of adherence 
to therapy should be emphasized to patients.
As patients moved through adaptation to new normal, 
physicians had the chance to remind and reassure patients 
of the safety of drug and disease monitoring. Patients with 
either metastatic or primary GIST were hypervigilant about 
physical changes. Regular checkups during this stage offered 
physicians the opportunity to remind patients of the need for 
adherence to therapy, to reinforce to patients the favorable 
tolerability of TKIs, and to ensure the best possible long-
term care. Most patients with GIST undergo surgery at 
some point in their patient journey, whether to remove the 
primary tumor or the metastases. Coordination and consistent 
communication are important between the different disciplines 
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(ie, oncologists and surgeons), as well as with the patients. 
This also presents an opportunity for physicians to help patients 
make distinctions between side-effects associated with TKI 
therapy and those occurring for other reasons (eg, invasive 
surgical procedures, illnesses unrelated to GIST) so patients 
do not mistakenly attribute discomfort or side-effects to their 
medicine with potentially consequent-reduced adherence.
Limitations
Inclusion in this voluntary study involved patients who were 
actively engaged and aware of their disease, and many patients 
participating in this study were driven to gather information; 
this may reflect a potential selection bias. Multiple data col-
lection techniques were used in this study to lessen these 
effects. Furthermore, it is important to note that the degree 
of personal advocacy demonstrated by interviewed patients 
in this study may not be representative of the GIST patient 
population as a whole. Nonetheless, the general GIST patient 
population may require more HCP and staff guidance than the 
patients participating in this study. Although care was taken 
to accommodate cultural and health care system differences 
across the participating countries, these factors may also 
influence patient perceptions.
Conclusion
The GIST patient journey is evolving as more information 
becomes available and patients become further educated 
about the disease. Most patients with GIST are highly self-
directed and understand the importance of adherence to 
TKI therapy, while acknowledging that therapy may have an 
impact on their daily lives. HCPs can optimize adherence by 
managing patient expectations about therapy duration and 
dissociating medication side-effects from postsurgical events 
where appropriate. Each phase of the patient journey offers 
opportunities for physicians and staff, and drug manufactur-
ers to provide support to patients.
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